SACUBITRIL/VALSARTAN: A NEW PARADIGM IN HEART FAILURE

Authors

  • Sunil Pai Kasturba Medical College, Mangalore, Manipal University
  • Priyanka Kamath Kasturba Medical College, Mangalore, Manipal University

Abstract

ABSTRACT
Heart failure (HF) is a syndrome whose cardinal symptoms are dyspnea and fatigue leading to a progressive decrease in exercise capacity. Drugs
currently used include angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers (ARB), diuretics, alone or in combination, and in
the cases where indicated, digoxin. Sacubitril/valsartan represents a new approach to treatment since the drug complex is made up of moieties
of sacubitril, a neprilysin inhibitor and valsartan, an ARB. Since sacubitril and valsartan, inhibit neprilysin and block the angiotensin receptor,
respectively, the drug molecule can be considered to play a central role by causing a dual inhibition of both the pathways that play an important
role in the pathogenesis of HF. It was approved in July 2015 by the US Food and Drug Administration to reduce the risk of cardiovascular death and
hospitalization for HF in patients with chronic HF (NYHA Class II-IV) and reduced ejection fraction. Symptomatic hypotension and angioedema were
the major side effects reported from clinical trials. The trials are currently being done to study its effects in HF preserved ejection fraction, chronic
kidney disease, and aortic stiffness; the results of which are awaited.
Keywords: Sacubitril/valsartan, Neprilysin inhibitor, Dual neutral endopeptidaseneprilysin renin-angiotensin system Inhibition.

Downloads

Download data is not yet available.

References

REFERENCES

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH,

et al. ACCF/AHA guideline for the management of heart failure:

A Report of the American College of Cardiology Foundation/American

Heart Association Task Force on Practice Guidelines. Circulation

;128(16):240-327.

Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB,

et al. Executive summary: Heart disease and stroke statistics--2013

update: A report from the American Heart Association. Circulation

;127(1):143-52.

Vardeny O, Miller R, Solomon SD. Combined neprilysin and reninangiotensin

system

inhibition for

the treatment

of

heart failure.

JACC

Heart

Fail 2014;2(6):663-70.

Publication Committee for the VMAC Investigators (Vasodilatation in

the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin

for treatment of decompensated congestive heart failure: A randomized

controlled trial. JAMA 2002;287(12):1531-40.

Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term

risk of death after treatment with nesiritide for decompensated heart

failure: A pooled analysis of randomized controlled trials. JAMA

;293(15):1900-5.

O’Connor CM, Starling RC, Hernandez AF, Armstrong PW,

Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with

acute decompensated heart failure. N Engl J Med 2011;365(1):32-43.

Ando S, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison

of candoxatril and atrial natriuretic factor in healthy men . Effects

on hemodynamics, sympathetic activity, heart rate variability, and

endothelin. Hypertension 1995;26:1160-6.

McDowell G, Nicholls DP. The endopeptidase inhibitor, candoxatril,

and its therapeutic potential in the treatment of chronic cardiac failure

in man. Expert Opin Investig Drugs 1999;8(1):79-84.

Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase

inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre

Dose-ranging Study Investigators. Lancet 1998;351(9116):1657-8.

Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E.

Omapatrilat and enalapril in patients with hypertension: The

Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.

Am J Hypertens 2004;17(2):103-11.

Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK,

et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril

on exercise tolerance and morbidity in patients with heart failure:

IMPRESS randomised trial. Lancet 2000;356(9230):615-20.

Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ,

Rouleau JL, et al. Comparison of omapatrilat and enalapril in

patients with chronic heart failure: The Omapatrilat Versus Enalapril

Randomized Trial of Utility in Reducing Events (OVERTURE).

Circulation 2002;106(8):920-6.

Feng L, Karpinski PH, Sutton P, Liu Y, Hook DF, Hu B, et al. LCZ696:

A dual-acting sodium supramolecular complex. Tetrahedron Lett

;53(3):275-6.

FDA. Press Announcements - FDA Approves New Drug to Treat Heart

Failure. Available from: http://www.fda.gov/NewsEvents/Newsroom/

PressAnnouncements/ucm453845.htm. [Last cited on 2016 Jan 15].

Asian J Pharm Clin Res, Vol 9, Issue 3, 2016, 37-40

Kamath and Pai

European Medicines Agency. News and events - New medicine to

treat heart failure recommended for approval. Available from: http://

www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/

news/2015/09/news_detail_002401.jsp&mid=WC0b01ac058004d5c1.

[Last cited on 2016 Jan 16].

Braunwald E. The path to an angiotensin receptor antagonistneprilysin

inhibitor in

the treatment of

heart failure. J

Am

Coll Cardiol

;65(10):1029-41.

Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M,

Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of

LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor

(ARNi). J Clin Pharmacol 2010;50(4):401-14.

Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP.

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor

of the angiotensin II receptor and neprilysin: A randomised,

double-blind, placebo-controlled, active comparator study. Lancet

;375(9722):1255-66.

Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-

Molessa A, et al. Efficacy and safety of LCZ696, a first-in-class

angiotensin receptor neprilysin inhibitor, in Asian patients with

hypertension: A randomized, double-blind, placebo-controlled study.

Hypertension 2014;63(4):698-705.

Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E,

et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart

failure with preserved ejection fraction: A phase 2 double-blind

randomised controlled trial. Lancet 2012;380(9851):1387-95.

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR,

et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure.

N Engl J Med 2014;371(11):993-1004.

FDA. Entresto - Prescribing Information. Available from: http://www.

pharma.us.novartis.com/product/pi/pdf/entresto.pdf. [Last cited on

Jan 15].

Published

01-07-2016

How to Cite

Pai, S., and P. Kamath. “SACUBITRIL/VALSARTAN: A NEW PARADIGM IN HEART FAILURE”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 4, July 2016, pp. 37-40, https://mail.innovareacademics.in/journals/index.php/ajpcr/article/view/11771.

Issue

Section

Review Article(s)